scispace - formally typeset
M

Maximilian Andreas Storz

Researcher at University of Freiburg

Publications -  7
Citations -  84

Maximilian Andreas Storz is an academic researcher from University of Freiburg. The author has contributed to research in topics: Vegan Diet & Medicine. The author has an hindex of 1, co-authored 7 publications receiving 3 citations.

Papers
More filters
Journal ArticleDOI

What makes a plant-based diet? a review of current concepts and proposal for a standardized plant-based dietary intervention checklist.

TL;DR: A review of the use of the term "plant-based diet" in nutrition intervention studies is presented in this paper. But the focus of the review was to investigate how researchers use the term and what types of food a plant-based dietary intervention may include.
Journal ArticleDOI

A Vegan Diet Is Associated with a Significant Reduction in Dietary Acid Load: Post Hoc Analysis of a Randomized Controlled Trial in Healthy Individuals

TL;DR: In this paper, a randomized controlled trial was conducted to examine whether an isocaloric vegan diet lowers dietary acid load (DAL) as compared to a meat-rich diet, which was determined using potential renal acid load and net endogenous acid production (NEAP) scores at baseline and after 3 and 4 weeks.
Journal ArticleDOI

Lifestyle Adjustments in Long-COVID Management: Potential Benefits of Plant-Based Diets

TL;DR: In this paper, the authors investigated whether a plant-based diet could reduce the burden of long-COVID and found that adoption of a plantbased diet leads to a reduced intake in pro-inflammatory mediators and could be one accessible strategy to tackle long COVID associated prolonged systemic inflammation.
Journal ArticleDOI

Changes in Gut Microbiota after a Four-Week Intervention with Vegan vs. Meat-Rich Diets in Healthy Participants: A Randomized Controlled Trial.

TL;DR: In this paper, a 4-week, monocentric, randomized, controlled trial with a parallel group design (vegan (VD) vs. meat-rich (MD)) with 53 healthy, omnivore, normal-weight participants (62% female, mean 31 years of age), fecal samples were collected at the beginning and at the end of the trial and were analyzed using 16S rRNA gene amplicon sequencing (Clinical Trial register: DRKS00011963).